These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
202 related articles for article (PubMed ID: 37029056)
21. A Clinical Guide to Combination Lipid-Lowering Therapy. Russell C; Sheth S; Jacoby D Curr Atheroscler Rep; 2018 Mar; 20(4):19. PubMed ID: 29516190 [TBL] [Abstract][Full Text] [Related]
22. [Hypercholesterolemia and cardiovascular risk]. Sinning D; Landmesser U Dtsch Med Wochenschr; 2023 Aug; 148(16):1025-1032. PubMed ID: 37541292 [TBL] [Abstract][Full Text] [Related]
23. Getting to an ImprOved Understanding of Low-Density Lipoprotein-Cholesterol and Dyslipidemia Management (GOULD): Methods and baseline data of a registry of high cardiovascular risk patients in the United States. Cannon CP; de Lemos JA; Rosenson RS; Ballantyne CM; Liu Y; Yazdi D; Elliott-Davey M; Mues KE; Bhatt DL; Kosiborod MN; Am Heart J; 2020 Jan; 219():70-77. PubMed ID: 31726422 [TBL] [Abstract][Full Text] [Related]
25. Cardiovascular Outcomes and Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors: Current Data and Future Prospects. Duprez DA; Handelsman Y; Koren M Vasc Health Risk Manag; 2020; 16():403-418. PubMed ID: 33116551 [TBL] [Abstract][Full Text] [Related]
26. An estimation of the consequences of reinforcing the 2016 and 2019 European Society of Cardiology/European Atherosclerosis Society guidelines on current lipid-lowering treatment in patients with type 2 diabetes in tertiary care-a SwissDiab study. Singeisen H; Renström F; Laimer M; Lehmann R; Bilz S; Brändle M Eur J Prev Cardiol; 2023 Oct; 30(14):1473-1481. PubMed ID: 37226890 [TBL] [Abstract][Full Text] [Related]
27. Low-density lipoprotein cholesterol lowering treatment: the current approach. Crismaru I; Pantea Stoian A; Bratu OG; Gaman MA; Stanescu AMA; Bacalbasa N; Diaconu CC Lipids Health Dis; 2020 May; 19(1):85. PubMed ID: 32375792 [TBL] [Abstract][Full Text] [Related]
28. Use of negative control outcomes to assess the comparability of patients initiating lipid-lowering therapies. Levintow SN; Orroth KK; Breskin A; Park AS; Flores-Arredondo JH; Dluzniewski P; Navar AM; Sørensen HT; Brookhart MA Pharmacoepidemiol Drug Saf; 2022 Apr; 31(4):383-392. PubMed ID: 34894377 [TBL] [Abstract][Full Text] [Related]
33. The Effect of PCSK9 Inhibitors on LDL-C Target Achievement in Patients with Homozygous Familial Hypercholesterolemia: A Retrospective Cohort Analysis. Alshahrani A; Kholaif N; Al-Khnifsawi M; Zarif H; Mahzari M Adv Ther; 2024 Feb; 41(2):837-846. PubMed ID: 38169062 [TBL] [Abstract][Full Text] [Related]
34. Lipid lowering therapy in primary and secondary prevention in Austria: are LDL-C goals achieved? : Results from the DA VINCI study. Siostrzonek P; Brath H; Zweiker R; Drexel H; Hoelzl R; Hemetsberger M; Ray KK Wien Klin Wochenschr; 2022 Apr; 134(7-8):294-301. PubMed ID: 34870742 [TBL] [Abstract][Full Text] [Related]
35. Statins, Ezetimibe, and Proprotein Convertase Subtilisin-Kexin Type 9 Inhibitors to Reduce Low-Density Lipoprotein Cholesterol and Cardiovascular Events. O'Keefe JH; DiNicolantonio JJ; Lavie CJ Am J Cardiol; 2017 Feb; 119(4):565-571. PubMed ID: 28081940 [TBL] [Abstract][Full Text] [Related]
36. Relationship Between Low-Density Lipoprotein Cholesterol, Free Proprotein Convertase Subtilisin/Kexin Type 9, and Alirocumab Levels After Different Lipid-Lowering Strategies. Rey J; Poitiers F; Paehler T; Brunet A; DiCioccio AT; Cannon CP; Surks HK; Pinquier JL; Hanotin C; Sasiela WJ J Am Heart Assoc; 2016 Jun; 5(6):. PubMed ID: 27287699 [TBL] [Abstract][Full Text] [Related]
37. A practical approach to the cholesterol guidelines and ASCVD prevention. Cho L Cleve Clin J Med; 2020 May; 87(5 suppl 1):15-20. PubMed ID: 32349970 [TBL] [Abstract][Full Text] [Related]
38. PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease. Schmidt AF; Carter JL; Pearce LS; Wilkins JT; Overington JP; Hingorani AD; Casas JP Cochrane Database Syst Rev; 2020 Oct; 10(10):CD011748. PubMed ID: 33078867 [TBL] [Abstract][Full Text] [Related]
39. ESC/EAS guidelines for the detection, prevention, and treatment of individuals at risk of a first myocardial infarction: effect of 5 years of updates and the new SCORE2. Sulman D; Zeitouni M; Silvain J; Kerneis M; Guedeney P; Barthélémy O; Brugier D; Sabouret P; Lattuca B; Mertens E; Posson J; Procopi N; Salloum T; Collet JP; Montalescot G Eur Heart J Cardiovasc Pharmacother; 2022 Sep; 8(6):633-643. PubMed ID: 35381063 [TBL] [Abstract][Full Text] [Related]